

WHAT'S AT STAKE WHEN PUSHING INNOVATION IN AMR RESEARCH?

HOW DO COMMERCIALISATION STRATEGIES AFFECT THE **KNOWLEDGE AND** ACTIONS PRODUCED AGAINST AMR? 3D life

WHERE DOES AMR RESEACH AND INNOVATION **dCod 1.0** FIT WITHIN THE NORWEGIAN BIOECONOMY?



DigiBiotics

INBioPharm



ECHNOLOGY RESERACH WITH A FCOUS ON


DIGITALIZATION, CONVERGENCE AND INNOVATION

Res publica - Responsibility, practice and the public good across Digital Life Norway

Participants: Heidrun Åm, Knut H. Sørensen, Ana Delgado, Roger strand, Gisle Solbu, Sissel Småland Aasheim, Anne Bremer

> BIOTECHNOLOGY FUNDING SHALL STIMULATE A BIO-ECONOMY AND SOLVE SOCIETAL CHALLENGES, BUT HOW WELL DO THESE TWO AIMS GO TOGETHER? WITHIN ANTIMICROBIAL RESISTANCE, THE PHARMA INDUSTRY HAS WITHDRAWN FROM INVESTING IN INNOVATIVE RESEARCH. DUE TO THE QUICK ADAPTION OF MICROORGANISMS, NEW ANTIBIOTICS QUICKLY MISS THEIR EFFECTIVENESS AND NEED TO BE REPLACED. THUS, THEY GENERATE LITTLE PROFIT FOR THE PHARMA INDUSTRY. STILL, MANY PUBLIC RESEARCH PROJECTS PURSUE RESEARCH TO SOLVE THE ISSUE OF AMR. PUBLIC FUNDING ORGANISATIONS INVEST INTO THESE BIOTECHNOLOGY PROJECTS IN ORDER TO GENERATE VALUE AND CREATE JOBS. HOWEVER, AMR RESEARCH RESTS UNEASY AT THIS INTERFACE BECAUSE OF THE BEFORE MENTIONED CHALLENGES OF TRANSLATING RESEARCH RESULTS INTO COMMERCIAL PRODUCTS. THUS, CONTRIBUTING TO A BIOECONOMY BASED ON ANTIBIOTICS MIGHT BE A PARTICULARLY DIFFICULT ENDEAVOUR.

WITHIN THE CONTEXT OF THE "DIGITAL LIFE NORWAY" RESEARCH CENTRE. THE "RES PUBLICA" PROJECT WILL EXPLORE HOW INNOVATION COORDINATORS, POLICY MAKERS AND SCIENTISTS CONSTRUCT KNOVLEDLEDGE AND ACTION AGAINST AMR, WITH A PARTICULAR EMPHASIS ON THEIR INNOVATION AND COMMERCIALISATION STRATEGIES. WE ASK: WHAT ISSUES MIGHT BE AT STAKE WHEN AMR RESERACH ALSO SOULD BE INNOVATION?



Auromega

APT





